พอดคาสท์ Impact Medicom ชั้นนำ (2024)

1
Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape 17:37

4M ago17:37

17:37

In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest: Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba. If you enjoyed our podcast episode, please revie…

1
Highlights from EHA 2024 - Updates on the Treatment of CLL 42:13

6M ago42:13

42:13

In this podcast episode, three of Canada’s top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis of the data from 6 oral presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is p…

1
LIVE FROM EHA 2024 - Sonrotoclax plus Zanubrutinib in R/R CLL 16:33

6M ago16:33

16:33

In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examined the efficacy and safety of sonrotoclax plus zanubrutinib for the treatment of R/R CLL. Our Guest: Dr. Stephen Opat is the direct…

1
Cutting Edge Advances in the Treatment of Lung Cancer 15:13

8M ago15:13

15:13

In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer vaccines and new targeted therapies. Our Guest: Dr. Barbara Melosky Dr Melosky is a Professor of Medicine at the University of British Columbia and a Med…

1
Precision Medicine Series: Ep15: Biomarkers in Upper GI Cancers 41:28

8M ago41:28

41:28

Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker (pathologist) discuss the latest biomarkers that may inform treatment of upper GI cancer. Our Guests: Dr. Christine Brezden-Masley Dr. Brezden-Masley is a …

1
Immunotherapy for Kidney Transplant Patients with Skin Cancer 21:32

9M ago21:32

21:32

In this podcast episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant. Our guest: Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers.…

1
Management of Cutaneous Squamous Cell Carcinoma (cSCC): A Surgeon’s Perspective 24:11

9M ago24:11

24:11

In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule version: https://www.youtube.com/watch?v=uk5JEUjbkDE&t=127s. Our Guest: Dr. S. Mark Taylor is a Facial Plastic and Reconstructive surgeon in Halifax, …

1
LIVE FROM ASH 2023: Isa-CYBORD induction chemotherapy in newly diagnosed, transplant eligible MM 16:58

1y ago16:58

16:58

In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice. Our Guests: Dr. Rami Kotb is a physician in the Division of Hematology, Department of Medical Oncology & Hematology at CancerCare Manitoba, Win…

1
Live from ASH 2023: Dr Brown Discusses Updated Results of the ALPINE Trial in CLL 13:48

1y ago13:48

13:48

In this episode of our podcast, recorded at the American Society of Hematology (ASH) in San Diego, California, we discuss updated results of the ALPINE trial with Dr. Jennifer Brown. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. Our Guest: Dr. Jennifer Brown is the Director of the CLL C…

1
First-line treatment strategies for the management of la/mUC: S2 Ep 5 - ESMO 2023: Discussion on 1L LA/mUC 32:28

1y ago32:28

32:28

In this video capsule series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This fifth episode of the series was recorded live from ESMO 2023 with Dr. Thomas Powles, who presented results of the EV-302 trial, and Dr. Normand Blais, Dr. Srikala Sridhar, and Dr. Bernie…

1
First Line la/mUC Evolving Treatment Strategies: S2 Ep 4 - Round Table Discussion 26:41

1+ y ago26:41

26:41

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg…

1
First Line la/mUC Evolving Treatment Strategies: S2 Ep 3 - Case Discussion 8:07

1+ y ago8:07

8:07

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg…

1
First Line la/mUC Evolving Treatment Strategies: S2 Ep 2 - First-Line Treatment 14:52

1+ y ago14:52

14:52

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg…

1
First Line la/mUC Evolving Treatment Strategies: S2 Ep 1 - Unmet Needs 10:38

1+ y ago10:38

10:38

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg…

1
Precision Medicine Series: Ep14: External Quality Assurance in Biomarker Testing 39:04

1+ y ago39:04

39:04

Welcome to our podcast episode on external quality assurance (or eQA) for testing biomarkers in oncology, hosted by Anna Christofides. In this episode, we discuss with Dr. Emina Torlakovic, the use of eQA to aid in the improvement of biomarker testing in Canada . Our Guest: Dr. Emina Torlakovic is a Professor in Department of Laboratory Medicine an…

1
Podcast Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - EP4: Hyperglycemia 29:52

1+ y ago29:52

29:52

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this fourth episode, we discuss the management of hyperglycemia associated with enfortumab vedotin, or EV. Our Guests: This fourth episode on the management of neuropathy is hosted by Dr Nimira Alimohamed, …

1
Podcast Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - EP1: Introduction to EV 16:05

1+ y ago16:05

16:05

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this first episode, we discuss the evolution of therapy from chemotherapy to treatment with novel therapies such as enfortumab vedotin, or EV. We then focus on the key clinica…

1
Podcast Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - EP2: Skin Reactions 30:08

1+ y ago30:08

30:08

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this second episode, we discuss the management of skin reactions associated with enfortumab vedotin, or EV. Our Guests: In this episode, Dr. Normand Blais, who is a medical on…

1
Podcast Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - EP3: Peripheral Neuropathy 22:47

1+ y ago22:47

22:47

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this third episode, we discuss the management of peripheral neuroptathy associated with enfortumab vedotin, or EV. Our Guests: This third episode on the management of neuropathy is hosted by Dr Srikala Srid…

1
Live from CCOLD - Treatment of CLL 30:40

1+ y ago30:40

30:40

In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the latest updates in the treatment of CLL with Dr. Laurie Sehn, Dr. Matthew Davies, and Dr. Constantine Tam. Our Guests: Dr. Sehn Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the Un…

1
Live from CCOLD: Dr Davids Discusses the ALPINE Trial in CLL 17:05

2y ago17:05

17:05

In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the results of the ALPINE trial with Dr. Matthew Davies. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. In this episode, Dr. Davids discusses the impa…

1
Precision Medicine Series: Ep13: Biomarkers in Endometrial Cancer 35:53

2y ago35:53

35:53

Welcome to our 13th podcast episode in the Precision Medicine Series. In this episode, hosted by Anna Christofides, we discuss diagnostic, prognostic and predictive biomarkers for the treatment of endometrial cancer. Our Guests: Dr. Jessica McAlpine, a Gynaecologic Oncologist and Division Head in the Division of Gynaecologic Oncology at the Univers…

1
Highlights from ASH: Canadian Perspective on the ALPINE Trial in CLL 15:19

2y ago15:19

15:19

Live From ASH, New Orleans: In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the American Society of Hematology meeting in New Orleans. Our Guest: Dr Sehn is a Clinical Assistant Professor in the Depar…

1
ASH Highlights - ALPINE Trial Shows Improved Efficacy and Safety Profile of Zanubrutinib vs Ibrutinib in CLL 14:34

2y ago14:34

14:34

Live From ASH, New Orleans: In this episode, Dr. Jennifer Brown discusses results of the phase 3 ALPINE trial, presented as a late breaking abstract at the American Society of Hematology (ASH) meeting 2022 in New Orleans, LA. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJ…

1
Emerging Treatments for Advanced, Unresectable Biliary Tract Cancer 14:56

2y ago14:56

14:56

In this episode we discuss current and emerging systemic treatments for advanced, unresectable biliary tract cancers, as well as the barriers to accessing new treatments in Canada. Our Guest: Dr. Howard Lim is a Medical Oncologist, specializing in the treatment of gastrointestinal cancers at the BC Cancer Agency in Vancouver and Clinical Associate …

1
Precision Medicine in Oncology Podcast Series: Ep12. Biomarkers for the treatment of breast cancer 37:49

2+ y ago37:49

37:49

Welcome to our 12th episode in the precision medicine in oncology podcast series. In this episode we discuss diagnostic, prognostic and predictive biomarkers for the treatment of breast cancer. Our Guest: Our guest for this episode is Dr. David Cescon, a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, O…

1
COVID-19 Pre-Exposure Prophylaxis - Ep4: Protecting Immunocompromised Patients 22:29

2+ y ago22:29

22:29

Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this third episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with cancer who are not able to mount a sufficient antibody response to vaccination. Our Guest: Our guest is Dr. Cowan, who is an Associate Scientist at Th…

1
COVID-19 Pre-Exposure Prophylaxis - Ep3: Patients with Cancer 35:21

2+ y ago35:21

35:21

Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this third episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with cancer who are not able to mount a sufficient antibody response to vaccination. Our Guest: Our guest is Dr. Dimas Yusuf, Medical Oncologist and specia…

1
COVID-19 Pre-Exposure Prophylaxis - Ep2: Patients with Hematological Malignancies 14:57

2+ y ago14:57

14:57

Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this second episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with hematological malignancies who are not able to mount a sufficient antibody response to vaccination. Our Guest: Our guest is Dr Laurie Sehn, Clinical …

1
COVID-19 Pre-Exposure Prophylaxis - Ep1: A pharmacist perspective (French) 21:57

2+ y ago21:57

21:57

Bienvenue dans la série de balados d’IMPACT Medicom sur la prophylaxie contre la COVID-19. Notre invitée Notre invitée dans l’épisode d’aujourd’hui est Annick Dufour, chef adjointe au département de pharmacie du CISSS Montérégie-Centre, au Québec au niveau des soins pharmaceutiques, de la recherche clinique et de l’oncologique. Elle est pharmacienn…

1
Treatment of Advanced Urothelial Carcinoma – A Discussion of EV-301 12:57

2+ y ago12:57

12:57

Welcome to our podcast episode on the treatment of urothelial carcinoma. In this episode, hosted by Anna Christofides, we discuss updated results of the Phase 3 EV-301 trial, presented at ASCO 2022, that examined the efficacy and safety of Enfortumab Vedotin, or EV, versus chemotherapy in patients with previously treated locally advanced or metasta…

1
Immunotherapy for Cervical Cancer 18:56

2+ y ago18:56

18:56

In this episode, we discuss immunotherapy treatment and biomarker testing for metastatic cervical cancer. Our Guest: Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynecology at Dalhousie University, Halifax, Canada. Dr. Bentley is Past President of the International Federation of Cervical Pathology and Colposcopy (IF…

1
Immunotherapy in HNSCC Series: Ep 3 - Role of the Medical Oncologist 12:33

2+ y ago12:33

12:33

In this episode of IMPACT Medicom’s podcast series on immunotherapies in Head and Neck Squamous Cell Carcinoma, we discuss the medical oncologist’s role in managing patients with HNSCC, and how immunotherapies fit in to their practice. Our Guest: Dr. Martin Smoragiewicz is a Medical Oncologist at the Odette Cancer Centre, part of Sunnybrook Health …

1
Precision Medicine in Oncology: Ep.11. Selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer 15:53

2+ y ago15:53

15:53

Welcome to episode 11 of our Precision Medicine in Oncology series. In this episode, we discuss the development of a pan-Canadian consensus paper on the selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer. Our Guest: Our guest for this episode is Dr. Anna Tinker, Medical Oncologist at BC Cancer in Vancouver, …

1
Immunotherapy in HNSCC Series: Ep 2 - Perspectives from Surgical Oncology 14:13

2+ y ago14:13

14:13

Welcome to the second episode of IMPACT Medicom’s podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas (HNSCC). This episode includes a discussion of: The role of the surgical oncologist in managing patients with HNSCC How immunotherapy fits into to the surgical oncologist's practice Our Guest: Our guest is Dr. Antoine Eskander…

1
Immunotherapy in HNSCC Series: Ep 1 - PD-L1 testing 12:45

2+ y ago12:45

12:45

Welcome to the first episode of IMPACT Medicom’s podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas. This episode includes a discussion of: The role of the pathologist in the management of head and neck cancers PD-L1 testing as a predictive biomarker for immunotherapy in HNSCC Improving the testing process for PD-L1 Our Guest…

1
Triple Negative Breast Cancer: Immunotherapies and Biomarkers 16:01

3y ago16:01

16:01

In this episode, we discuss the treatment of triple negative breast cancer (TNBC) with Dr. Stephen Chia. We cover: The use of immunotherapies to treat TNBC Biomarkers that can determine which patients will best respond to immunotherapies The challenges of testing for PDL-1 Our Guest: Dr. Stephen Chia is a professor in the division of medical oncolo…

1
Prophylaxis de la COVID-19: Protection des patients immunodéprimés - Ep5 - Introduction (Francais) 12:08

3y ago12:08

12:08

Bienvenue à la série de fichiers balados d’IMPACT Medicom sur la vaccination contre la COVID-19. Roula Drossis est l’animatrice de l’épisode d’aujourd’hui. Dans cet épisode, nous discutons de l'immunisation contre la COVID-19 et de la façon dont nous pouvons protéger nos populations les plus vulnérables qui ne sont pas en mesure de produire une rép…

1
Pre- and Post- COVID-19 Exposure Prophylaxis: Ep4 - Hematologic Malignancies 18:18

3y ago18:18

18:18

In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination. In this fourth episode of the series, we discuss: Response to COVID-19 vaccines in the general population Response to …

1
Pre- and Post- COVID-19 Exposure Prophylaxis: Ep3 - A Pharmacist Perspective 23:35

3y ago23:35

23:35

In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination. In this third episode of the series, we discuss: Response to COVID-19 vaccines in the general population Response to C…

1
Pre- and Post- COVID-19 Exposure Prophylaxis: Ep1 - Introduction 14:42

3y ago14:42

14:42

In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination. In this first episode of the series, we discuss: Response to COVID-19 vaccines in the general population Populations w…

1
Pre- and Post- COVID-19 Exposure Prophylaxis: Ep2 - Solid Organ Transplant 21:49

3y ago21:49

21:49

In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination. In this second episode of the series, we discuss: Response to COVID-19 vaccines in the general population Response to …

1
Precision Medicine in Oncology: Ep.10. Biomarkers in Gastrointestinal Malignancies 25:50

3y ago25:50

25:50

In this episode of IMPACT Medicom’s Precision Medicine in Oncology podcast series, we discuss the evolving biomarker landscape in gastrointestinal malignancies and some of the advantages and challenges of implementing and accessing biomarker testing. Our guest: Dr. Rosalyn Juergens is a medical oncologist with clinical expertise in lung and esophag…

1
Precision Medicine in Oncology: Ep.9 DEBATE - Is PARP inhibitor maintenance therapy in first-line BRCA mutated ovarian cancer a curative-intent strategy? 22:10

3y ago22:10

22:10

Welcome to episode 9 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the second episode in a 3-part series on ovarian cancer. This episode, hosted by IMPACT Medicom’s Sarah Doucette, features a debate on whether first-line maintenance therapy with PARP inhibitors can be considered a curative strategy in patients with advanced,…

1
Precision Medicine in Oncology: Ep.8. Importance of BRCA testing for Advanced Epithelial Ovarian Cancer 20:12

3y ago20:12

20:12

Welcome to episode 8 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the first in a series of episodes focusing on ovarian cancer. In this episode, we discuss the importance of BRCA testing for patients with advanced epithelial ovarian cancer and how national initiatives have helped to improve BRCA testing standards across the…

1
Precision Medicine in Oncology Podcast Series: Ep7. Importance of Genetic Testing in Patients with Prostate Cancer 23:31

3y ago23:31

23:31

In this seventh episode of our podcast series on precision medicine, hosted by Anna Christofides, we discuss genomic testing in prostate cancer. Our episode focuses on the evolution and uptake of genetic testing in prostate cancer. We discuss testing for homologous recombination repair (HRR) genes and their association with prognosis and influence …

1
Precision Medicine in Oncology: Ep.6 Biomarker testing in metastatic colorectal cancer – mismatch repair and beyond 31:46

3y ago31:46

31:46

Welcome to episode 6 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology. In this episode Dr. Gonzalez discusses testing methodology, particularly for mismatch repair deficiency, as well as potential emerging biomarkers for metastatic colorectal cancer. Our Guest: Dr. Raul Gonzalez is an Associate Professor of Pathology at Harvard …

1
Zanubrutinib for the Treatment of Waldenstrom's Macroglobulinemia 35:46

3y ago35:46

35:46

In this episode of our podcast, we discuss the use of zanubrutinib for the treatment of Waldenstrom’s Macroglobulinemia. Our episode discusses data from the Phase 3 ASPEN trial, comparing the efficacy and safety of zanubrutinib with ibrutinib in these patients. Our Guests Our first guest, Dr. Constantine Tam, is a Professor of Hematology at the Uni…

1
Precision Medicine in Oncology: Ep.5 Precision medicine for metastatic colorectal cancer 22:22

3y ago22:22

22:22

In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss: · The current standards for molecular testing in metastatic colorectal cancer · The potential benefit of a Canadian guideline for molecular testing in metastatic colorectal cancer Our guest: Dr. Sharlene Gill is Professor of Medicine at the University o…

1
Lung Cancer Screening: Ontario 33:54

3+ y ago33:54

33:54

Background Lung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics) Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer ca…

พอดคาสต์ที่ควรค่าแก่การฟัง

Impact Medicom พอดคาสต์

พอดคาสต์ที่ควรค่าแก่การฟัง

คู่มืออ้างอิงด่วน